Hafnium oxide nanoparticles activated by radiotherapy for the treatment of solid tumors

ASTRO, San Antonio, Texas · 2018, J. O. Thariat et al.

Authors

Thariat J. O.1, Le Tourneau C.2, Chajon Rodriguez E.3, Sargos P.4, Le Pechoux C.5, Kantor G.6, Hoffmann C.7, Moreno Garcia V.7, De Baere T.5, Vendrely V.8, Rio E.9, Lecesne A.10, Gronchi A.11, Nguyen P. L.12, Dicker A. P.13, Seiwert T. Y.14, Papai Z.15, Rutkowski P.16, Bonvalot S.2

1 – Radiation Oncology, Centre François Baclesse, Caen, France
2 – Institut Curie, Paris, France
3 – Centre Eugène Marquis – Département de Radiothérapie, Rennes, France
4 – Department of Radiation Oncology. Institut Bergonie, Bordeaux, France
5 – Institut Gustave Roussy, Villejuif, France
6 – Department of Radiotherapy, Institut Bergonié, Bordeaux, France
7 – START Madrid, Madrid, Spain
8 – University Hospital of Bordeaux, Bordeaux, France
9 – Institut de Cancérologie de l’Ouest, Nantes, France
10 – Service d’Oncologie médicale Gustave Roussy, Villejuif, France
11 – Istituto Nazionale Tumori, Milan, Italy
12 – Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
13 – Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA
14 – University of Chicago, Chicago, IL
15 – Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary
16 – Centrum Onkologii-Instytut im. Sklodowskiej-Curie w Warszawie, Warszawa, Poland

Summary

To improve radiotherapy (RT) in terms of tumor response and to reduce irradiation of healthy tissues, innovative therapeutic approaches are needed. In response, NBTXR3, injectable hafnium oxide nanoparticles, was developed for the treatment of solid tumors.

Once injected intratumorally, NBTXR3 can deposit high energy within tumors only when activated by an ionizing radiation source, like current standard RTs. Upon activation, the high energy radiation physically kills the tumor cells by triggering DNA damage and cell destruction improving clinical outcomes.

Since its first successful clinical evaluation in a completed phase I trial in patients with locally advanced soft tissue sarcoma, NBTXR3 is currently evaluated in numerous indications worldwide (EU, Asia, US).

NBTXR3 have shown promising results in non-clinical studies with marked antitumor efficacy and in clinical development in terms of safety and preliminary evaluations of efficacy. Considering the preliminary results of the 145 patients injected across all clinical trials, these first-in-class nanoparticles have already proven to be an encouraging innovative treatment in various types of tumors. The last patient of the phase II/III trial in STS was included and the results of this study regarding efficacy and safety will soon be disclosed.

Read Article

Contact

Pour plus d’informations, contactez notre équipe des affaires médicales à l’adresse medicalaffairs@nanobiotix.com

Prochain